A multicenter, open-label, single-arm trial of the long-term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE-02).
Yushi HirotaYasumasa KakeiJunta ImaiHideki KatagiriKen EbiharaJun WadaJunichi SuzukiTatsuhiko UrakamiTakashi OmoriWataru OgawaPublished in: Journal of diabetes investigation (2024)
Empagliflozin demonstrated a certain level of safety and efficacy for the treatment of insulin resistance syndrome and lipoatrophic diabetes over 52 weeks, confirming its potential as a therapeutic option.
Keyphrases
- insulin resistance
- type diabetes
- open label
- clinical trial
- adipose tissue
- metabolic syndrome
- study protocol
- glycemic control
- cardiovascular disease
- phase ii
- polycystic ovary syndrome
- randomized controlled trial
- radiation therapy
- case report
- combination therapy
- replacement therapy
- rectal cancer
- smoking cessation
- preterm birth
- gestational age
- weight loss
- locally advanced